🔎 Trials Near Me

Home › Leiomyosarcoma › Texas

Pag-aaral pangklinika para sa Leiomyosarcoma sa Texas

7 pag-aaral para sa Leiomyosarcoma ang naghahanap ng mga kalahok sa mga site sa Texas.

Mga Lungsod sa Texas

Opisyal na teksto ng pag-aaral (English)

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

  • UT MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06498648

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • M D Anderson Cancer Center, Houston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT04031677

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

  • UT MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT05711615

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

  • MD Anderson Cancer Center, Houston
  • NEXT Houston, Houston
  • NEXT Dallas, Irving
  • at 2 pa
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06975293

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

  • MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT07633756

Metastatic Leiomyosarcoma Biomarker Protocol

  • MD Anderson, Houston
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT05653388

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

  • MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT06789172

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.